Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Radiotherapy with concomitant chemotherapy for head and neck cancer.

E E Vokes1, A M Awan, R R Weichselbaum

  • 1Department of Medicine, University of Chicago, Pritzker School of Medicine, Illinois.

Hematology/Oncology Clinics of North America
|August 1, 1991
PubMed
Summary

Chemoradiotherapy improves survival for head and neck cancer patients. More aggressive regimens show promise but increase toxicities like mucositis, requiring further study before widespread use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

"Timing is Everything": the evolving role of immune checkpoint inhibition in nasopharyngeal carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

Area of Science:

  • Oncology
  • Radiation Oncology
  • Head and Neck Cancer Research

Background:

  • Concomitant chemoradiotherapy significantly improves disease-free and overall survival in head and neck cancer.
  • Previous successes were achieved with single-agent chemotherapy, showing modest survival gains.
  • Recent trials explore aggressive chemotherapy with split-course radiotherapy, yielding promising response and survival rates.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of advanced chemoradiotherapy regimens in head and neck cancer.
  • To compare newer, more aggressive treatment schedules against standard radiotherapy.
  • To determine the role of intensified chemoradiotherapy in managing advanced head and neck malignancies.

Main Methods:

  • Review of phase II trials investigating novel chemoradiotherapy schedules.

Related Experiment Videos

  • Analysis of response and survival data from these trials.
  • Assessment of treatment-related toxicities, particularly mucositis.

    • Main Results:

    • Encouraging response and survival figures reported in phase II trials for aggressive chemoradiotherapy.
    • Increased toxicity, notably mucositis, observed with more intensive regimens.
    • Observed survival improvements, though statistically significant, have been relatively small.

    Conclusions:

    • Aggressive chemoradiotherapy regimens show potential for improved outcomes in head and neck cancer.
    • Increased toxicity, including mucositis, is a significant concern with these intensified schedules.
    • Further randomized trials are necessary to validate these findings and compare them to standard radiotherapy alone; current use outside trials is not recommended.